The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - PharmaMar; Tecnofarma
Consulting or Advisory Role - GlaxoSmithKline; PharmaMar
Research Funding - Adaptimmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb/Pfizer (Inst); Celgene (Inst); Deciphera (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Prognostic value of EZH2 expression for immunotherapy-based schemes in advanced soft-tissue sarcoma: A translational research from Spanish Group of Research on Sarcoma (GEIS).
 
David Silva Moura
Honoraria - Tecnofarma
Research Funding - Eisai; Immix BioPharma (Inst); Novartis (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Bayer; Celgene; Eisai; Pfizer; PharmaMar
 
Jorge Zamora
No Relationships to Disclose
 
Nadia Hindi
No Relationships to Disclose
 
Maria Lopez-Alvarez
No Relationships to Disclose
 
Serena Lacerenza
No Relationships to Disclose
 
Giovanni Grignani
Honoraria - Bayer; Eisai; GlaxoSmithKline; Lilly; Merck Serono; Novartis; Pfizer; Pfizer; PharmaMar
Consulting or Advisory Role - Bayer; Eisai; GlaxoSmithKline; Merck; PharmaMar
Speakers' Bureau - GlaxoSmithKline; GlaxoSmithKline
Research Funding - PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar; tesaro
 
Javier Martinez-Trufero
Consulting or Advisory Role - Eisai; PharmaMar
Research Funding - Blueprint Medicines (Inst); Lilly (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Merck; PharmaMar
 
Andres Redondo
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; PharmaMar
Research Funding - Eisai (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar
 
Claudia Maria Valverde Morales
No Relationships to Disclose
 
Silvia Stacchiotti
Honoraria - Aadi; GlaxoSmithKline; PharmaMar
Consulting or Advisory Role - Astex Pharmaceuticals; Bavarian Nordic; Bayer; Daiichi Sankyo; Deciphera; Epizyme; GlaxoSmithKline; Ikena Oncology; MaxiVax; Novartis; PharmaMar; Rain Therapeutics
Research Funding - Advenchen Laboratories (Inst); Amgen (Inst); Bayer (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); SpringWorks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Antonio Lopez-Pousa
No Relationships to Disclose
 
Antonio Gutierrez
Consulting or Advisory Role - Abbvie; AstraZeneca Spain; Incyte; Janssen; Takeda
Speakers' Bureau - Abbvie; AstraZeneca Spain; Janssen; Takeda
 
Jose A. Lopez-Martin
Employment - Pharmamar-zeltia
Stock and Other Ownership Interests - PharmaMar
Consulting or Advisory Role - Amgen; Amgen; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Caris Life Sciences; Celgene; GlaxoSmithKline; Lilly; MSD Oncology; Novartis; Pfizer; PharmaMar; Pierre Fabre; Roche; Roche Molecular Diagnostics (Inst)
Patents, Royalties, Other Intellectual Property - PharmaMar
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology; MSD Oncology; Roche; Roche
 
Javier Martin Broto
Honoraria - Bayer; Eisai; GlaxoSmithKline; Lilly; Novartis; PharmaMar; Tecnofarma
Consulting or Advisory Role - Amgen; Asofarma; Bayer; GlaxoSmithKline; Lilly; Novartis; PharmaMar; Roche; Tecnofarma
Speakers' Bureau - PharmaMar
Research Funding - Amgen (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai; Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Nektar (Inst); Novartis; Novartis (Inst); Pfizer (Inst); PharmaMar
Expert Testimony - Novartis; PharmaMar
Travel, Accommodations, Expenses - Pfizer; PharmaMar